180 related articles for article (PubMed ID: 32808978)
1. Identification of Functional HLA-A*01:01-Restricted Epstein-Barr Latent Membrane Protein 2-Specific T-Cell Receptors.
Huisman W; Gille I; van der Maarel LE; Hageman L; Morton LT; de Jong RCM; Heemskerk MHM; Amsen D; Falkenburg JHF; Jedema I
J Infect Dis; 2022 Sep; 226(5):833-842. PubMed ID: 32808978
[TBL] [Abstract][Full Text] [Related]
2. Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.
Zheng Y; Parsonage G; Zhuang X; Machado LR; James CH; Salman A; Searle PF; Hui EP; Chan AT; Lee SP
Cancer Immunol Res; 2015 Oct; 3(10):1138-47. PubMed ID: 25711537
[TBL] [Abstract][Full Text] [Related]
3. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
4. Generation of Epstein-Barr Virus Antigen-Specific T Cell Receptors Recognizing Immunodominant Epitopes of LMP1, LMP2A, and EBNA3C for Immunotherapy.
Dudaniec K; Westendorf K; Nössner E; Uckert W
Hum Gene Ther; 2021 Sep; 32(17-18):919-935. PubMed ID: 33798008
[TBL] [Abstract][Full Text] [Related]
5. Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapy.
Lammoglia Cobo MF; Welters C; Rosenberger L; Leisegang M; Dietze K; Pircher C; Penter L; Gary R; Bullinger L; Takvorian A; Moosmann A; Dornmair K; Blankenstein T; Kammertöns T; Gerbitz A; Hansmann L
Cytotherapy; 2022 Aug; 24(8):818-826. PubMed ID: 35525797
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination.
Ranieri E; Herr W; Gambotto A; Olson W; Rowe D; Robbins PD; Kierstead LS; Watkins SC; Gesualdo L; Storkus WJ
J Virol; 1999 Dec; 73(12):10416-25. PubMed ID: 10559360
[TBL] [Abstract][Full Text] [Related]
8. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vector.
Yang D; Shao Q; Sun H; Mu X; Gao Y; Jiang R; Hou J; Yao K; Chen Y; Sun B
Clin Dev Immunol; 2011; 2011():716926. PubMed ID: 21969838
[TBL] [Abstract][Full Text] [Related]
10. Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells.
Kuzushima K; Hayashi N; Kudoh A; Akatsuka Y; Tsujimura K; Morishima Y; Tsurumi T
Blood; 2003 Feb; 101(4):1460-8. PubMed ID: 12393434
[TBL] [Abstract][Full Text] [Related]
11. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.
Cho HI; Kim UH; Shin AR; Won JN; Lee HJ; Sohn HJ; Kim TG
Br J Cancer; 2018 Feb; 118(4):534-545. PubMed ID: 29360818
[TBL] [Abstract][Full Text] [Related]
12. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2.
Meij P; Leen A; Rickinson AB; Verkoeijen S; Vervoort MB; Bloemena E; Middeldorp JM
Int J Cancer; 2002 May; 99(1):93-9. PubMed ID: 11948498
[TBL] [Abstract][Full Text] [Related]
13. Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: A novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma.
Jurgens LA; Khanna R; Weber J; Orentas RJ
J Clin Immunol; 2006 Jan; 26(1):22-32. PubMed ID: 16418800
[TBL] [Abstract][Full Text] [Related]
14. Induction of the Epstein-Barr virus latent membrane protein 2 antigen-specific cytotoxic T lymphocytes using human leukocyte antigen tetramer-based artificial antigen-presenting cells.
Lu XL; Liang ZH; Zhang CE; Lu SJ; Weng XF; Wu XW
Acta Biochim Biophys Sin (Shanghai); 2006 Mar; 38(3):157-63. PubMed ID: 16518539
[TBL] [Abstract][Full Text] [Related]
15. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.
Orentas RJ; Roskopf SJ; Nolan GP; Nishimura MI
Clin Immunol; 2001 Feb; 98(2):220-8. PubMed ID: 11161978
[TBL] [Abstract][Full Text] [Related]
16. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
Lee SP; Thomas WA; Murray RJ; Khanim F; Kaur S; Young LS; Rowe M; Kurilla M; Rickinson AB
J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972
[TBL] [Abstract][Full Text] [Related]
17. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.
Sinha D; Srihari S; Beckett K; Le Texier L; Solomon M; Panikkar A; Ambalathingal GR; Lekieffre L; Crooks P; Rehan S; Neller MA; Smith C; Khanna R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589524
[TBL] [Abstract][Full Text] [Related]
18. CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients.
Lin X; Gudgeon NH; Hui EP; Jia H; Qun X; Taylor GS; Barnardo MC; Lin CK; Rickinson AB; Chan AT
Cancer Immunol Immunother; 2008 Jul; 57(7):963-75. PubMed ID: 18094968
[TBL] [Abstract][Full Text] [Related]
19. Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression.
Li J; Zhang XS; Xie D; Deng HX; Gao YF; Chen QY; Huang WL; Masucci MG; Zeng YX
Cancer Biol Ther; 2007 Dec; 6(12):1997-2004. PubMed ID: 18087217
[TBL] [Abstract][Full Text] [Related]
20. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
